
|Videos|August 14, 2017
Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer
Author(s)Christine M. Lovly, MD, PhD
Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial
3
New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC
4
EMA Validates T-DXd for First-Line HER2+ Metastatic Breast Cancer
5














































